Hepatobiliary neoplasm

Summary

Hepatobiliary neoplasm (MONDO:0002514) is a cancer and 13 clinical trials. Top therapeutic interventions include chlorotrianisene and dkn-01. A subtype of hepatobiliary disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 13

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hepatobiliary neoplasm
Mondo ID	MONDO:0002514
EFO	EFO:0008550
DOID	DOID:0080355
NCIT	C8614
UMLS	C0854196
MedGen	208891
Anatomy (UBERON)	UBERON:0002423
Is cancer (heuristic)	yes

Also known as: hepatic and biliary neoplasms · hepatic and biliary tumors · hepatic and biliary tumours · hepatic, biliary, and gallbladder neoplasms · hepato-biliary neoplasm · hepato-biliary tumor · hepato-biliary tumour · hepatobiliary benign neoplasm · hepatobiliary neoplasm · hepatobiliary system neoplasm · hepatobiliary system neoplasm (disease) · hepatobiliary system tumor · hepatobiliary system tumour · hepatobiliary tumor · hepatobiliary tumors · hepatobiliary tumour · hepatobiliary tumours · liver and biliary neoplasm · liver and biliary system neoplasm · neoplasm of hepatobiliary system (+2 more)

Disease family

This is a subtype of hepatobiliary disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › hepatobiliary neoplasm

Related subtypes (3): biliary tract disorder, liver disorder, gallbladder disorder

Subtypes (2): gallbladder neoplasm, liver and intrahepatic bile duct neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 13.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE2	4
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01020812	PHASE1/PHASE2	TERMINATED	Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
NCT01151761	PHASE2	TERMINATED	Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
NCT03818997	PHASE2	WITHDRAWN	Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
NCT04010071	PHASE2	UNKNOWN	Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
NCT04642664	PHASE2	COMPLETED	Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer
NCT00767234	Not specified	TERMINATED	Permission to Collect Blood Over Time for Research
NCT01135849	Not specified	COMPLETED	B-Receptor Signaling in Cardiomyopathy
NCT02715089	Not specified	UNKNOWN	Precise Treatment in Hepatobiliary Cancers (PTHBC)
NCT04501913	Not specified	COMPLETED	Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
NCT04709445	Not specified	UNKNOWN	Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses
NCT04959630	Not specified	COMPLETED	Immersive Virtual Reality Environment for Complex Cognitive Skills Curricular Training in Liver Surgery
NCT06049836	Not specified	COMPLETED	Holographic Augmented Reality Versus Screen Visualisation of 3D Rendering Models for the Pre-operative Evaluation and Planning of Liver Resections
NCT06397430	Not specified	COMPLETED	Nutritional Support for Patients Operated for Malignant Tumors in HPD Zone

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CHLOROTRIANISENE	4	1
DKN-01	2	1